Jilin Aodong: Announcement on the completion of the general election of the board of directors and the appointment of senior managers and securities affairs representatives
Securities code: 000623 Securities abbreviation: Jilin Aodong Announcement number: 2026-036
Jilin Aodong Pharmaceutical Group Co., Ltd.
Regarding the completion of the general election and appointment of the Board of Directors
Announcements from Senior Management and Securities Affairs Representatives
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete, and contains no false records, misleading statements or major omissions.
Jilin Aodong Pharmaceutical Group Co., Ltd. (hereinafter referred to as the "Company") held the company's first extraordinary shareholders' meeting in 2026 and the first meeting of the 12th board of directors on July 17, 2026, completed the election of the 12th board of directors, and reviewed and approved relevant proposals such as the election of chairman, vice chairman, special committee members of the board of directors, and the appointment of senior managers and securities affairs representatives of the company. The relevant information is now announced as follows:
1. Composition of the 12th Board of Directors of the Company
Non-independent directors: Mr. Li Xiulin, Ms. Guo Shuqin, Mr. Yang Kai, Ms. Zhang Shuyuan, Mr. Wang Zhenyu, Mr. Zhao Dalong
Independent directors: Ms. Zhang Chunying, Ms. Chen Yating, Mr. Liu Shiming
Mr. Li Xiulin serves as the Chairman of the 12th Board of Directors of the company, and Ms. Guo Shuqin serves as the Vice Chairman of the 12th Board of Directors of the Company. The term of directors of the twelfth board of directors is three years, from July 17, 2026 to July 17, 2029.
The total number of directors who concurrently serve as senior managers of the company and employee representatives in the twelfth session of the board of directors of the company does not exceed one-half of the total number of directors of the company. The above-mentioned personnel have the qualifications and work experience to perform the corresponding job responsibilities and are capable of fulfilling the responsibilities and requirements of the positions they are hired for. The qualifications and independence of the independent directors have been reviewed by the Shenzhen Stock Exchange and there is no objection.
2. Composition of the special committees of the 12th Board of Directors of the Company
Director of Strategy Committee: Guo Shuqin
Members: Zhao Dalong, Chen Yating (independent directors)
Chairman of the Audit Committee: Zhang Chunying (Independent Director)
Members: Zhao Dalong, Chen Yating (independent directors)
Chairman of the Nomination Committee: Liu Shiming (Independent Director)
Members: Zhang Chunying (independent director), Wang Zhenyu
Director of the Remuneration and Appraisal Committee: Chen Yating (Independent Director)
Members: Zhang Shuyuan, Liu Shiming (independent directors)
Chairman of the Investment Committee: Yang Kai
Members: Zhang Shuyuan, Wang Zhenyu
The term of office of each special committee member of the 12th Board of Directors shall commence from the date of review and approval at the first meeting of the 12th Board of Directors to the expiration date of the 12th Board of Directors, that is, from July 17, 2026 to July 17, 2029.
3. The company’s appointment of senior managers and securities affairs representatives
General Manager: Ms. Guo Shuqin
Deputy General Manager: Mr. Yang Kai, Ms. Zhang Shuyuan, Mr. Wang Zhenyu, Mr. Lin Xiaolin, Mr. Wang Chao Financial Director: Ms. Zhang Shuyuan
Secretary of the Board of Directors: Mr. Wang Zhenyu
Securities affairs representative: Mr. Zhao Renhe
The above-mentioned senior managers and securities affairs representatives (see the attachment for resume details) all have the qualifications and abilities suitable for the exercise of their powers. The qualifications and appointment procedures are in compliance with relevant laws, regulations, normative documents and the Articles of Association. Their term is the same as the term of the 12th Board of Directors of the company, that is, from July 17, 2026 to July 17, 2029. Mr. Wang Zhenyu, secretary of the board of directors, and Mr. Zhao Renhe, securities affairs representative, have obtained board secretary qualification certificates recognized by the Shenzhen Stock Exchange, and their qualifications comply with relevant laws and regulations.
4. Contact information of secretary of the board of directors and securities affairs representative
Mailing address: No. 2158 Aodong Street, Dunhua City, Jilin Province
Contact number: 0433-6238973
Fax: 0433-6238973
Email: [email protected]
5. Resignation of some directors upon expiration of their term of office
Now that the term of the 11th Board of Directors has expired, Mr. Li Peng and Ms. Xiao Weiwei will no longer serve as independent directors of the company and will no longer hold other positions in the company. The company and the board of directors express their sincere gratitude to Mr. Li Peng and Ms. Xiao Weiwei for their diligent work and contribution to the company during their tenure!
Announcement is hereby made.
Jilin Aodong Pharmaceutical Group Co., Ltd. Board of Directors
July 18, 2026
Attachment: Resumes of senior managers and securities affairs representatives
(1) Ms. Guo Shuqin, born in December 1963, has a college degree, is a senior accountant, senior economist, and a member of the Communist Party of China. From January 1984 to September 1986, he served as the accountant of the financial department of Yanbian Aodong Pharmaceutical Factory. From October 1986 to July 1988, he studied at Yanbian Finance and Trade College. From August 1988 to January 1990, he served as the accountant of the financial department of Yanbian Aodong Pharmaceutical Factory. From February 1990 to May 1991, he served as the accountant in charge of the financial department of Yanbian Aodong Pharmaceutical Factory. In 1991 From June 1992 to December 1992, he served as the deputy section chief of the Finance Department of Yanbian Aodong Pharmaceutical Factory. From January 1993 to December 1993, he served as the chief of the Finance Section of Yanbian Aodong Pharmaceutical Factory. From January 1994 to July 1995, he served as the Finance Minister of Yanbian Aodong Pharmaceutical (Group) Co., Ltd. From July 1995 to 1997 In August 2000, he served as director and finance minister of Yanbian Aodong Pharmaceutical (Group) Co., Ltd. From August 1997 to February 2000, he served as director and deputy general manager of Yanbian Aodong Pharmaceutical (Group) Co., Ltd. (renamed Jilin Aodong Pharmaceutical Group Co., Ltd. in October 1998). From February 2000 to January 2002, he served as director and executive deputy general manager of Jilin Aodong Pharmaceutical Group Co., Ltd. in 2002. From January 2017 to July 2017, he served as director of Jilin Aodong Pharmaceutical Group Co., Ltd. and chairman and general manager of Jilin Aodong Yanbian Pharmaceutical Co., Ltd. From July 2017 to present, he served as vice chairman and general manager of Jilin Aodong Pharmaceutical Group Co., Ltd. and chairman and general manager of Jilin Aodong Yanbian Pharmaceutical Co., Ltd. Ms. Guo Shuqin does not have the circumstances listed in Article 3.2.2 of the "Shenzhen Stock Exchange Self-Regulatory Guidelines for Listed Companies No. 1 - Standardized Operation of Main Board Listed Companies"; Ms. Guo Shuqin is one of the parties to the concerted action agreement of the actual controller of the company, and has no related relationship with other directors and senior managers of the company; Ms. Guo Shuqin directly holds 2,026,789 shares of the company The shares held through Jilin Aodong Pharmaceutical Group Co., Ltd.-Phase 1 Employee Stock Ownership Plan correspond to 1,040,000 shares of the company. shares; have not been punished by the China Securities Regulatory Commission and other relevant departments or disciplined by stock exchanges in the past five years; have not been investigated by judicial authorities for suspected crimes or investigated by the China Securities Regulatory Commission for suspected violations of laws and regulations; have not committed any breach of trust; and have qualifications that meet the requirements of relevant laws, administrative regulations, departmental rules, normative documents, the "Shenzhen Stock Exchange Stock Listing Rules" and other relevant regulations of the exchange.
(2) Mr. Yang Kai, born in March 1977, is a master’s degree candidate, senior economist, accountant, and member of the Communist Party of China. From June 1996 to January 2003, he served as deputy director of the accounting and finance department of Yanbian Aodong Pharmaceutical (Group) Co., Ltd. (renamed Jilin Aodong Pharmaceutical Group Co., Ltd. in October 1998). From January 2003 to May 2004, he served as director and chief accountant of Yanbian Highway Construction Co., Ltd. (stock code: 000776, now renamed GF Securities Co., Ltd.) in 2004. From May 2007 to July 2007, he served as director and financial director of Jilin Aodong Pharmaceutical Group Co., Ltd., from July 2007 to June 2011, he served as deputy general manager of Jilin Aodong Pharmaceutical Co., Ltd., from June 2011 to December 2012, he served as internal control director of Jilin Aodong Pharmaceutical Group Co., Ltd., from December 2012 to December 2013. From January 2014 to July 2017, he served as the director, deputy general manager and financial director of Yanbian Shixian Bailu Paper Co., Ltd., and from January 2014 to July 2017, he served as the internal control director of Jilin Aodong Pharmaceutical Group Co., Ltd. From July 2017 to the present, he served as the director and deputy general manager of Jilin Aodong Pharmaceutical Group Co., Ltd. Mr. Yang Kai does not have any of the circumstances listed in Article 3.2.2 of the "Shenzhen Stock Exchange Self-Regulatory Guidelines for Listed Companies No. 1 - Standardized Operation of Main Board Listed Companies"; Mr. Yang Kai is one of the parties to the concerted action agreement of the actual controller of the company, and has no related relationship with other directors and senior managers of the company; Mr. Yang Kai directly holds 158,527 shares of the company shares, the shares held through Jilin Aodong Pharmaceutical Group Co., Ltd.-Phase 1 Employee Stock Ownership Plan correspond to 195,000 shares of the company shares; have not been punished by the China Securities Regulatory Commission and other relevant departments or disciplined by stock exchanges in the past five years; have not been investigated by judicial authorities for suspected crimes or investigated by the China Securities Regulatory Commission for suspected violations of laws and regulations; have not committed any breach of trust; and have qualifications that meet the requirements of relevant laws, administrative regulations, departmental rules, normative documents, the "Shenzhen Stock Exchange Stock Listing Rules" and other relevant regulations of the exchange.
(3) Ms. Zhang Shuyuan, born in December 1972, holds a bachelor's degree, is a senior accountant, senior economist, and a member of the Communist Party of China. From July 1992 to January 1997, he served as the accountant of Dunhua Forestry Machinery Factory. From January 1997 to January 1999, he served as the clerk of the audit department of Dunhua Forestry Machinery Factory. From January 1999 to March 2004, he served as the accountant in charge of Dunhua Thermal Oil Furnace Manufacturing Factory. From March 2004 to March 2006, he served as the accountant of Jilin Aodong Yanbian Pharmaceutical Co., Ltd., in 2006 From March 2007 to June 2007, he served as the deputy director and director of the Finance Department of Jilin Aodong Yanbian Pharmaceutical Co., Ltd. From June 2007 to July 2017, he served as the financial director of Jilin Aodong Pharmaceutical Group Co., Ltd. From July 2017 to the present, he served as the deputy general manager and financial director of Jilin Aodong Pharmaceutical Group Co., Ltd. From July 2020 to the present, he served as the director of Jilin Aodong Pharmaceutical Group Co., Ltd. Ms. Zhang Shuyuan does not have any of the circumstances listed in Article 3.2.2 of the "Shenzhen Stock Exchange Self-Regulatory Guidelines for Listed Companies No. 1 - Standardized Operation of Main Board Listed Companies"; she has no relationship with the company, controlling shareholders or actual controllers; she has no relationship with other directors and senior managers of the company; Ms. Zhang Shuyuan directly holds 158,527 shares of the company. shares, the shares held through Jilin Aodong Pharmaceutical Group Co., Ltd.-Phase 1 Employee Stock Ownership Plan correspond to 195,000 shares of the company shares; have not been punished by the China Securities Regulatory Commission and other relevant departments or disciplined by stock exchanges in the past five years; have not been investigated by judicial authorities for suspected crimes or investigated by the China Securities Regulatory Commission for suspected violations of laws and regulations; have not committed any breach of trust; and have qualifications that meet the requirements of relevant laws, administrative regulations, departmental rules, normative documents, the "Shenzhen Stock Exchange Stock Listing Rules" and other relevant regulations of the exchange.
(4) Mr. Wang Zhenyu, born in December 1981, holds a master's degree and a bachelor's degree in economics and law. He is a senior economist and corporate legal consultant. From July 2004 to June 2009, he served as secretary of the board of directors office, assistant to the board secretary, and securities affairs representative of Jilin Aodong Pharmaceutical Group Co., Ltd. From July 2009 to February 2010, he served as secretary of the board of directors of Yanbian Highway Construction Co., Ltd. (during the period: in February 2010, it was renamed GF Securities Co., Ltd., stock code: 000776), from March 2010 to 2017 In July 2020, he served as the securities affairs representative of Jilin Aodong Pharmaceutical Group Co., Ltd. (during the period: from July 2014 to July 2017, he served as the employee supervisor of Jilin Aodong Pharmaceutical Group Co., Ltd., and from May 2024 to December 2025, he served as the supervisor of GF Securities Co., Ltd.). From July 2017 to present, he has served as the secretary of the board of directors of Jilin Aodong Pharmaceutical Group Co., Ltd., from July 2020 to present, he has served as director of Jilin Aodong Pharmaceutical Group Co., Ltd., and from January 2022 to present, he has served as deputy general manager of Jilin Aodong Pharmaceutical Group Co., Ltd. (during the period: from May 2013 to present, he has served as director of Zhongshan Public Small Loan Co., Ltd.). Mr. Wang Zhenyu does not have any of the circumstances listed in Article 3.2.2 of the "Self-Regulatory Guidelines for Listed Companies of Shenzhen Stock Exchange No. 1 - Standardized Operation of Main Board Listed Companies"; he has no relationship with the company, controlling shareholders, or actual controllers; he has no relationship with other directors and senior managers of the company; Mr. Wang Zhenyu directly holds 101,492 shares of the company, and holds 78,000 shares of the company through Jilin Aodong Pharmaceutical Group Co., Ltd. - Phase 1 Employee Stock Ownership Plan shares; have not been punished by the China Securities Regulatory Commission and other relevant departments or disciplined by stock exchanges in the past five years; have not been investigated by judicial authorities for suspected crimes or investigated by the China Securities Regulatory Commission for suspected violations of laws and regulations; have not committed any breach of trust; and have qualifications that meet the requirements of relevant laws, administrative regulations, departmental rules, normative documents, the "Shenzhen Stock Exchange Stock Listing Rules" and other relevant regulations of the exchange.
(5) Mr. Lin Xiaolin, born in August 1978, master's degree candidate, senior political engineer, associate researcher, and member of the Communist Party of China. From July 2002 to August 2004, he served as the platoon leader of the First Team of the Yanbian Prefecture Detachment of the Armed Police. From September 2004 to December 2004, he served as the acting instructor of the Yanji City Armed Police Squadron. From January 2005 to December 2006, he served as the instructor of the Yanji City Armed Police Squadron. From January 2007 to November 2009, From December 2009 to December 2014, he served as the deputy director of the Political Department of the Yanbian Prefecture Detachment of the Armed Police Force. From January 2015 to May 2018, he served as the deputy director of the Political Department of the Jilin City Armed Police Detachment. From May 2018 to March 2020, he served as the deputy political commissar and secretary of the Discipline Inspection Commission of the Armed Police Yanbian Prefecture Detachment. In 2020 Retired from active service in March 2020. From April 2020 to the present, he has served as the legal department manager of Jilin Aodong Pharmaceutical Group Co., Ltd.. From August 2020 to the present, he has served as the comprehensive office manager of Jilin Aodong Pharmaceutical Group Co., Ltd.. From July 2020 to January 2022, he has served as the supervisor of Jilin Aodong Pharmaceutical Group Co., Ltd.. From January 2022 to the present, he has served as the deputy general manager of Jilin Aodong Pharmaceutical Group Co., Ltd., 2022 From October 2016 to present, he serves as the general manager of Jilin Aodong Medicinal Seed Industry Technology Co., Ltd. Mr. Lin Xiaolin does not have any of the circumstances listed in Article 3.2.2 of the "Shenzhen Stock Exchange Self-Regulatory Guidelines for Listed Companies No. 1 - Standardized Operation of Main Board Listed Companies"; he has no relationship with the company, controlling shareholders or actual controllers; he has no relationship with other directors and senior managers of the company; Mr. Lin Xiaolin directly holds 20,010 shares of the company shares; have not been punished by the China Securities Regulatory Commission and other relevant departments or disciplined by stock exchanges in the past five years; have not been investigated by judicial authorities for suspected crimes or investigated by the China Securities Regulatory Commission for suspected violations of laws and regulations; have not committed any breach of trust; and have qualifications that meet the requirements of relevant laws, administrative regulations, departmental rules, normative documents, the "Shenzhen Stock Exchange Stock Listing Rules" and other relevant regulations of the exchange.
(6) Mr. Wang Chao, born in May 1975, holds a bachelor's degree and a bachelor's degree in medicine. From March 1999 to June 2001, he served as the sales representative of Shanghai Johnson & Johnson Pharmaceutical Co., Ltd.; from July 2001 to February 2003, he served as the sales supervisor of Xi'an Janssen Pharmaceutical Co., Ltd.; from March 2003 to April 2025, he successively served as the provincial manager, regional manager, deputy general manager, chairman and general manager of Jilin Aodong Pharmaceutical Co., Ltd. From April 2025 to present, he serves as deputy general manager of Jilin Aodong Pharmaceutical Group Co., Ltd. Mr. Wang Chao does not have any of the circumstances listed in Article 3.2.2 of the "Shenzhen Stock Exchange Self-Regulatory Guidelines for Listed Companies No. 1 - Standardized Operation of Main Board Listed Companies"; he has no relationship with the company, controlling shareholders, or actual controllers; he has no relationship with other directors and senior managers of the company; Mr. Wang Chao directly holds 74,600 shares of the company, and holds 45,500 shares of the company through Jilin Aodong Pharmaceutical Group Co., Ltd. - Phase 1 Employee Stock Ownership Plan shares; have not been punished by the China Securities Regulatory Commission and other relevant departments or disciplined by stock exchanges in the past five years; have not been investigated by judicial authorities for suspected crimes or investigated by the China Securities Regulatory Commission for suspected violations of laws and regulations; have not committed any breach of trust; and have qualifications that meet the requirements of relevant laws, administrative regulations, departmental rules, normative documents, the "Shenzhen Stock Exchange Stock Listing Rules" and other relevant regulations of the exchange.
(7) Mr. Zhao Renhe, born in February 1979, holds a bachelor’s degree, senior accountant, information system project manager, economist, network engineer, and member of the Communist Party of China. From July 2004 to February 2008, he served as a clerk in the Corporate Management Office of Jilin Aodong Yanbian Pharmaceutical Co., Ltd. From March 2008 to January 2009, he served as the supervisor of the Corporate Management Office of Jilin Aodong Yanbian Pharmaceutical Co., Ltd. From February 2009 to November 2009, he served as the deputy manager of the Information Technology Department of Jilin Aodong Yanbian Pharmaceutical Co., Ltd. from December 2009 to 2022 In October 2020, he served as the general manager of the Information Technology Department of Jilin Aodong Yanbian Pharmaceutical Co., Ltd. From December 2019 to December 2022, he served as the accountant of the financial department of Jilin Aodong Innovative Pharmaceutical Technology Co., Ltd. From November 2022 to the present, he served as the director of the office of the board of directors of Jilin Aodong Pharmaceutical Group Co., Ltd., and from April 2024 to the present, he served as the securities affairs representative of Jilin Aodong Pharmaceutical Group Co., Ltd. Mr. Zhao Renhe does not have any of the circumstances listed in Article 3.2.2 of the "Self-Regulatory Guidelines for Listed Companies of the Shenzhen Stock Exchange No. 1 - Standardized Operation of Main Board Listed Companies"; he has no relationship with the company, controlling shareholders or actual controllers; he has no relationship with other directors and senior managers of the company; Mr. Zhao Renhe holds a share of 26,000 shares of the company through Jilin Aodong Pharmaceutical Group Co., Ltd. - Phase 1 Employee Stock Ownership Plan shares; have not been punished by the China Securities Regulatory Commission and other relevant departments or disciplined by stock exchanges in the past five years; have not been investigated by judicial authorities for suspected crimes or investigated by the China Securities Regulatory Commission for suspected violations of laws and regulations; have not committed any breach of trust; and have qualifications that meet the requirements of relevant laws, administrative regulations, departmental rules, normative documents, the "Shenzhen Stock Exchange Stock Listing Rules" and other relevant regulations of the exchange.